Pseudouridimycin (PUM) is a novel antibiotic compound that belongs to the class of nucleoside analogs. It is characterized by its unique mechanism of action, which involves the inhibition of bacterial RNA polymerase, thereby disrupting RNA synthesis in susceptible bacteria. PUM exhibits broad-spectrum antibacterial activity, particularly against Gram-positive and some Gram-negative bacteria, making it a potential candidate for treating infections caused by resistant strains. The compound is notable for its structural similarity to uridine, which allows it to effectively mimic natural substrates in bacterial cells. Additionally, PUM has shown promising results in preclinical studies, demonstrating efficacy against various pathogens, including those resistant to conventional antibiotics. Its low toxicity profile and ability to penetrate bacterial membranes further enhance its therapeutic potential. Ongoing research aims to explore its pharmacokinetics, optimal dosing regimens, and potential applications in clinical settings, particularly in the face of rising antibiotic resistance. Overall, Pseudouridimycin represents a significant advancement in the search for new antimicrobial agents.

Pseudouridimycin (PUM)

1566586-52-4: Pseudouridimycin (PUM) is a novel antibiotic compound that belongs to the class of nucleoside analogs. It is characterized by its unique mechanism of action, which involves the inhibition of bacterial RNA polymerase, thereby disrupting RNA synthesis in susceptible bacteria. PUM exhibits broad-spectrum antibacterial activity, particularly against Gram-positive and some Gram-negative bacteria, making it a potential candidate for treating infections caused by resistant strains. The compound is notable for its structural similarity to uridine, which allows it to effectively mimic natural substrates in bacterial cells. Additionally, PUM has shown promising results in preclinical studies, demonstrating efficacy against various pathogens, including those resistant to conventional antibiotics. Its low toxicity profile and ability to penetrate bacterial membranes further enhance its therapeutic potential. Ongoing research aims to explore its pharmacokinetics, optimal dosing regimens, and potential applications in clinical settings, particularly in the face of rising antibiotic resistance. Overall, Pseudouridimycin represents a significant advancement in the search for new antimicrobial agents.

<p>Pseudouridimycin: a C-nucleoside antibiotic, inhibits bacterial RNAP, targets Gram-negative and Gram-positive bacteria.</p>

CAS 1566586-52-4

Pseudouridimycin (PUM)

Pseudouridimycin

Ref: TM-T16673

Pseudouridimycine

Ref: TR-P157385